Peyman H, Esterberg E, Obermuller D, Bartsch R. Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Dtsch Arztebl Int. 2024 Apr 9;19(1):26. doi: 10.1007/s11657-024-01380-9
Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.